by David Cassak
This is the second of a two-part series.
Device start-ups are still rare in Europe. But now a combination of factors--new venture money, more receptive public markets, and a new generation of entrepreneurs--is making device company creation less exotic.
by David Cassak
This is the second of a two-part series.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.